
|Videos|November 29, 2018
Assessing Barriers to Oral Oncolytic Adherence
Kathy Oubre, MS, Chief Operating Officer, Pontchartrain Cancer Center in Covington, Louisiana, shares some barriers to adherence to oral oncolytics that patients may face.
Advertisement
From financial toxicity to lifestyle, there are many factors that could prevent patients from consistently taking their medication. Kathy Oubre, MS, Chief Operating Officer, Pontchartrain Cancer Center in Covington, Louisiana, shares some barriers to adherence to oral oncolytics that patients may face.
There’s no way a checklist can be as comprehensive as it needs to be to cover all possible influential factors, Oubre said. Having a conversation with patients is the best way to get a clear understanding of what their barriers might be and how to overcome them.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Oncology Nursing News
1
FDA Approves Sevabertinib for HER2-Mutant Non-Small Cell Lung Cancer
2
FDA Approves Iberdomide: A New Oral Paradigm in Multiple Myeloma Care
3
FDA Camizestrant Approval: Nurses Key to New Breast Cancer Paradigm
4
Nursing Protocols for the New Oral RAS Inhibitor Daraxonrasib
5
















































